Lefty inhibitors belong to a distinct class of chemical compounds known for their pivotal role in regulating embryonic development and cell differentiation. These inhibitors are closely associated with the transforming growth factor-beta (TGF-β) superfamily of signaling molecules. To understand Lefty inhibitors, it's essential to appreciate their role within the intricate process of embryogenesis. During early development, Lefty inhibitors play a fundamental role in establishing the body plan of an organism. They are known for their function in maintaining symmetry and axis formation, a critical step in the early stages of embryonic development. Lefty inhibitors act as antagonists to certain signaling pathways within the TGF-β superfamily, exerting their influence by interfering with the signaling molecules involved. Specifically, they counteract the activity of Nodal, an important TGF-β member, which plays a key role in specifying the left-right axis in vertebrates. By doing so, Lefty inhibitors help ensure that the developing embryo forms with appropriate bilateral symmetry, preventing developmental abnormalities and ensuring the proper organization of vital organs.
Lefty inhibitors can be broadly classified into two isoforms: Lefty-1 and Lefty-2. Both isoforms exhibit similar mechanisms of action, working as negative regulators by binding to Nodal and inhibiting its signaling. This function is crucial for maintaining the balance of the Nodal pathway, preventing excessive or inappropriate signaling that could lead to developmental defects. Lefty inhibitors are a prime example of the delicate checks and balances that govern embryonic development. Their presence ensures the precise orchestration of signaling pathways, guaranteeing that an organism's body plan and symmetry are established correctly during its early stages of development. Understanding the mechanisms of Lefty inhibitors is not only essential for developmental biology but also holds potential implications for various fields of science and medicine, shedding light on the intricacies of cell signaling and differentiation.
Items 11 to 15 of 15 total
画面:
| 製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
|---|---|---|---|---|---|---|
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
ラパチニブは、チロシンキナーゼを阻害するEGFRとHER2のデュアル阻害剤で、HER2陽性乳房細胞の増殖と転移を阻害する。 | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
ベムラフェニブは、BRAF V600E変異を特異的に阻害し、この特異的変異を有するメラノーマ細胞の制御不能な増殖を阻止する。 | ||||||
Regorafenib | 755037-03-7 | sc-477163 sc-477163A | 25 mg 50 mg | $320.00 $430.00 | 3 | |
レゴラフェニブは、血管新生受容体、間質キナーゼ、発癌性キナーゼを標的とするマルチキナーゼ阻害薬で、成長と血管新生を制御するのに役立つ。 | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
オシメルチニブは、EGFR T790M変異を標的とするように設計されたEGFRチロシンキナーゼ阻害剤であり、非小細胞肺(NSCLC)患者における耐性を克服する。 | ||||||
5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | 1032900-25-6 | sc-505041 | 1 mg | $230.00 | ||
セリチニブはALKおよびROS1キナーゼを阻害し、特にALKまたはROS1遺伝子再配列を有する非小細胞肺がん(NSCLC)の研究で研究され、腫瘍増殖を阻害する。 | ||||||